Liaoning Cancer Hospital & Institute
105
24
32
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 105 trials
100.0%
+13.5% vs industry average
19%
20 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (105)
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
Role: collaborator
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Role: collaborator
The Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation Combined With Traditional Chinese Medicine on Gastrointestinal Function Recovery in Patients Undergoing Abdominal Surgery
Role: collaborator
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
Role: collaborator
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
Role: collaborator
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Role: collaborator
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
Role: collaborator
Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)
Role: collaborator
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
Role: collaborator
Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients
Role: collaborator
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Role: collaborator
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
Role: collaborator
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
Role: collaborator
Immune Cell Therapy for Advanced Solid Tumors
Role: collaborator
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Role: collaborator
Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
Role: lead
RT for Adenocarcinoma/Adenosquamous Carcinoma
Role: collaborator
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
Role: lead
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
Role: lead